Techniques and methods for judging resistance to crizotinib

Crizotinib, as a targeted drug, plays an important role in the treatment of non-small cell lung cancer (NSCLC). However, as treatment progresses, some patients may develop drug resistance. Timely and accurate judgment of whether resistance to crizotinib has developed is crucial for adjusting treatment plans and protecting patient health.

1. Observation of clinical manifestations

Patients should pay close attention to their clinical manifestations while taking crizotinib. If symptoms that were effectively controlled by the drug reappear or worsen, such as coughing, difficulty breathing, etc., this may indicate that drug resistance has developed. In addition, if the patient develops new symptoms, such as chest pain, hemoptysis, etc., the possibility of drug resistance should also be highly suspected.

2. Tumor marker detection

Tumor markers such as carcinoembryonic antigen (CEA) can be used as an important reference to determine whether crizotinib is resistant. During treatment, if the level of tumor markers continues to rise or rises suddenly, it may indicate a decrease in the drug's ability to control the tumor, that is, the development of drug resistance. Therefore, regular detection of tumor markers is of great significance for early detection of drug resistance.

3. Imaging examination

Imaging examination is the most direct and effective method to determine resistance to crizotinib. Through CT and other imaging technologies, changes in tumor size, shape, density and other changes can be visually observed. If the tumor appears to be significantly enlarged, multiplied, or new metastases appear while taking crizotinib, it can be determined to be drug-resistant. In addition, advanced imaging technologies such as PET-CT can more accurately evaluate tumor metabolism and drug efficacy.

4. Genetic testing

Gene testing is the scientific basis for determining resistance to crizotinib. By conducting genetic testing on the patient's tumor tissue or blood samples, it can be determined whether there are genetic mutations associated with crizotinib resistance. For example, secondary mutations or amplifications of the ALK gene may lead to resistance to crizotinib. Therefore, when signs of resistance appear, timely genetic testing can help clarify the resistance mechanism and guide subsequent treatment.